<unk>  is a fibroblast growth factor 23 (FGF23) blocking antibody that is FDA approved for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.   Common adverse reactions include headache, injection site reaction, vomiting, pyrexia, pain in extremity, vitamin D decreased.
Burosumab
Nebacumab
Alirocumab
Sarilumab
Evolocumab
Lanadelumab
Dupilumab
Ustekinumab